Patients Will Now Have Access to Affordable Zepbound Single-Dose Vials Through Ro’s Platform
Ro, a direct-to-consumer healthcare startup, has announced a new partnership with Eli Lilly to offer single-dose vials of the weight loss drug Zepbound at a more affordable price. The partnership aims to streamline access to the popular treatment, allowing eligible patients to receive a diagnosis, prescription, and delivery of the drug to their homes through Ro’s platform and app.
The single-dose vials of Zepbound will be available at a lower cost than the autoinjector form of the drug, with prices starting at $399 per month before insurance. This makes the drug more accessible to those who don’t have insurance coverage or are paying out of pocket.
Ro’s platform will offer a “complete end-to-end” experience, allowing patients to access doctors, labs, and a pharmacy all in one place. The company will also help eligible patients determine which form of the drug is best for them based on their insurance coverage.
The partnership comes as Eli Lilly is working to expand access to branded Zepbound in response to the growing demand for the drug and the limited supply of compounded versions. The FDA is currently reconsidering its decision to take Zepbound off its drug shortages list, which would prevent compounding pharmacies from making custom versions of the drug.
Ro’s CEO, Zachariah Reitano, stated that the goal of the new integration is to “break down barriers and provide patients with safe and effective options they can rely on.” The company will continue to work with patients to ensure they have access to the most effective and affordable products.
